New cocktail of drugs takes on Hard-to-Treat breast cancer
NCT ID NCT07581795
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a new combination of drugs—paclitaxel polymer micelles, trastuzumab, pertuzumab, and adebelimab—against the standard taxane-based regimen for people with advanced HER2-positive breast cancer. About 140 participants will be randomly assigned to one of the two groups. The goal is to see if the new combo shrinks tumors better and delays cancer growth, while also checking for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adebelimab
- What this could lead to
- If successful, this could offer a more effective first-line treatment option for advanced HER2-positive breast cancer, potentially improving tumor shrinkage and delaying disease progression.
- What could go wrong
- This is an early Phase 2 trial with only 140 participants, so results may not apply to all patients. The new drug combination may cause more side effects or not work better than the standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer center
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.